Moreover, our results also show that metabolic adaptation not only affects glioma proliferation but confers the cell with pro-survival mechanisms against PARP inhibitors; interestingly, we found that the combination with Etomoxir (a specific and irreversible inhibitor of carnitine palmitoyl transferase I (CPT1), the rate-limiting step in β-oxidation), inhibits respiration and growth of glioma cells, leading to a complete loss of cell fitness. The gene discussed is PARP1; the disease is central nervous system cancer.